Eribulin, also known by its brand name Halaven, is a chemotherapy drug used in the treatment of metastatic breast cancer and liposarcoma. It belongs to a class of medications called microtubule inhibitors, which work by disrupting the growth and division of cancer cells.

Eribulin is typically administered intravenously by a healthcare professional in a clinical setting. The dosage and frequency of treatment will vary depending on the individual patient’s condition and response to the drug. It is important to follow your healthcare provider’s instructions carefully and attend all scheduled appointments for monitoring and evaluation.

Like all medications, eribulin can cause side effects. Common side effects may include fatigue, nausea, hair loss, and decreased appetite. It is important to report any side effects to your healthcare provider promptly so that they can be managed effectively.

It is also important to inform your healthcare provider of any other medications or supplements you are taking, as they may interact with eribulin and affect its effectiveness or increase the risk of side effects.

As a medical professional, I recommend discussing the potential benefits and risks of eribulin with your healthcare provider to determine if it is the right treatment option for you. Your healthcare team is here to support you throughout your treatment journey and help you achieve the best possible outcomes.